Background: Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional randomized trials have been recently completed.
A nemia frequently complicates chronic kidney disease (CKD) (1) , in part because of deficient renal erythropoietin release (2) . Phase 1 and 2 clinical trials first evaluated recombinant human erythropoietin replacement therapy in 1986 and 1987 in patients receiving hemodialysis. These trials demonstrated dose-dependent increases in hemoglobin levels and avoidance of red blood cell transfusions (3-6), but they also reported incidence of hypertension and vascular thrombosis (3, 5, 6) . Subsequent randomized, placebo-controlled trials (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) concluded that erythropoietin treatment was associated with some improvement in quality of life at the expense of increased risk for hypertension and vascular thrombosis. From 1998 until 2009, all randomized trials compared 2 active erythropoiesis-stimulating agent (ESA) regimens to achieve higher and lower hemoglobin targets.
An earlier meta-analysis of 9 randomized trials involving 5143 patients with CKD concluded that targeting a higher hemoglobin concentration (typically 120 to 150 g/L) versus a lower concentration (95 to 115 g/L) was associated with an increased risk for all-cause mortality, arteriovenous access thrombosis, and hypertension (17) . Since then, a large placebo-controlled trial of darbepoetin in patients with diabetes mellitus and CKD (TREAT [Trial to Reduce Cardiovascular Events with Aranesp Therapy]) has been completed (18) .
In this present systematic review, we summarize the benefits and harms of treating anemia with an ESA and included data from all existing randomized trials. Using cumulative meta-analysis, we explore when the beneficial and harmful effects of ESA treatment and hemoglobin targets first became evident.
METHODS
We followed a prespecified and peer-reviewed study protocol (19) and substantively updated a previous review and added multiple additional analyses, including a cumulative meta-analysis.
Data Sources and Searches
Two independent authors searched MEDLINE (January 1966 to November 2009) and EMBASE (1980 to November 2009) by using optimally sensitive search strategies developed by the Cochrane Collaboration. They also searched the Cochrane Renal Group trial register and the Cochrane Central Register of Controlled Trials for randomized, controlled trials to November 2009. The Cochrane search was updated to March 2010. Appendix Table 1 (available at www.annals.org) includes the full search strategies. Two authors identified eligible trials according to the inclusion criteria and without language restriction. They resolved any disagreements by discussion with an arbitrator.
Study Selection
We included randomized, controlled trials of at least 3 months' duration that allocated patients to ESA versus placebo, no treatment, or different ESA doses to achieve a higher hemoglobin target versus a lower hemoglobin target. Trials of erythropoietin-alfa or -beta, darbepoetin, or a continuous erythropoietin receptor activator at any dose and route of administration were eligible. We assumed that placebo-controlled trials were comparing 2 treatment targets for hemoglobin, although explicit targets were not always described. Trials of populations with any stage of CKD were included.
Data Extraction and Quality Assessment
Two authors independently extracted data on characteristics of the participants, interventions, and clinical outcomes. Both reviewers also assessed the risks for bias in trials according to standard criteria (allocation concealment, blinding of patients, investigators and outcome assessors, completeness to follow-up, and use of intention-totreat analysis) (20) . The reviewers resolved any discrepancies in data extraction by discussion with an arbitrator.
Data Synthesis and Statistical Analysis
We summarized treatment effects as relative risks (RRs) for dichotomous outcomes or mean differences for continuous outcomes with 95% CIs by using the DerSimonian and Laird random-effects model to pool data. We tested for heterogeneity of treatment effects between studies with the Cochran Q and the I 2 statistics (21) . In cumulative meta-analysis, outcomes were accrued according to the year of publication. Through subgroup analysis and univariate random-effects meta-regression analysis, we investigated the impact of the following plausible effect modifiers on outcomes: stage of CKD (stage 2 to 5 not requiring dialysis vs. stage 5 requiring dialysis); trial design (ESA vs. ESA or ESA vs. placebo or no treatment); baseline hemoglobin concentration; age; proportion of trial participants with diabetes mellitus, hypertension, or cardiovascular disease; baseline blood pressure; duration of administration of the intervention (Ͻ6 months, 6 to 12 months, 12 to 24 months, or Ͼ24 months); blinding of patients, investigators, or outcome assessors; intention-to-treat analysis; study attrition (Ն10% or Ͻ10%); and number of trial participants (0 to 100, 101 to 500, or Ͼ500). Earlier studies tended to have very low event rates in 1 or both study groups. Our primary analyses used the standard continuity correction of 0.05 to estimate the RR for these trials. We also conducted a sensitivity analysis by using continuity corrections of 0.0001, 0.001, and 0.01 to evaluate the robustness of our results. We found no changes for the point estimates for treatment effects or their 95% CIs. All analyses were conducted with SAS, release 9.1 (SAS Institute, Cary, North Carolina).
Role of the Funding Source
No specific funding was received for any aspect of this study. All authors had full access to the study data and had final responsibility for the decision to submit the manuscript for publication.
RESULTS
We identified 27 randomized trials (10 452 participants) that met the inclusion criteria (Appendix Figure, available at www.annals.org). All were randomized, controlled trials that enrolled patients with CKD for treatment with ESA. The study design changed over time from smaller placebo-controlled trials with relatively lower hemoglobin targets to larger active comparator trials with higher hemoglobin targets. This change occurred around 1998, after about a decade of randomized trial research. It was heralded by the publication of a large trial (1233 pa-tients) by Besarab and colleagues (22) conducted in patients with end-stage kidney disease requiring hemodialysis for renal replacement therapy. Between 1989 and 1998, all 10 available trials enrolled fewer than 160 patients (median, 55 patients; interquartile range [IQR], 13 to 94 patients) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . From 1998 onward, trials were larger (median number of participants, 172; IQR, 91 to 600), and 3 trials included more than 1000 patients (18, 22, 23) . Earlier studies were conducted both in patients requiring dialysis and in those with earlier stages of CKD. After 2003, all but 1 (24) of 11 studies were performed in patients with moderate to severe CKD (estimated glomerular filtration rate ranged from 15 to 79 mL/min per 1.73 m 2 ). The treatment comparisons in the identified trials were either ESA (erythropoietin-alfa or -beta or darbepoetin) versus placebo or no treatment or different doses of ESA therapy as needed to achieve 2 (higher vs. lower) hemoglobin target levels. Doses of ESA used in the trials were not available in one third of the study reports (Appendix Table 2 , available at www.annals.org). Studies published before 1998 were all placebo-controlled (7-16), whereas trials published from 1998 until 2009 compared 2 different doses of ESA therapy (18, (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) . The exception to this more recent trend of active comparator trials was the largest study to date, published in 2009, which was again placebo-controlled (18) .
Trials completed before 1998 targeted a lower hemoglobin level in the high hemoglobin versus active ESA treatment groups than that of trials published later. With the exception of a trial of 14 patients with hemoglobin level targets between 126 and 133 g/L (10), the remaining smaller trials before 1998 had higher hemoglobin targets between 95 and 120 g/L (7-9, 12, 14) . Trials from 1998 to 2008, all using ESA as the active comparator, had higher hemoglobin targets between 120 to 150 g/L versus lower targets between 90 to 120 g/L (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) . In the more recent trials, the lower hemoglobin target range was similar to the higher range in older trials. In all trials, the median hemoglobin target achieved by treatment in the high hemoglobin groups was 130 g/L (IQR, 120 to 140 g/L) (10, 11, 16, 22, 24 -26, 28, 31-33, 36) ; the corresponding value in the low hemoglobin target groups was 101 g/L (IQR, 92 to 110 g/L) (11, 14, 16, 22, 24 -26, 28, 31-33, 36) .
Most studies enrolled participants between 50 and 60 years of age on average. In the 3 largest trials of more than 1000 patients each, patients were generally older than 60 years (18, 22, 23) . Two small studies were conducted in children (12, 26) . We identified 3 trials (1413 patients) that included only patients with established cardiovascular disease (22, 25, 30 ) and 2 trials (4210 patients) that included only patients with diabetes mellitus and CKD (18, 35) . Appendix Tables 2 and 3 (available at www.annals .org) summarize the characteristics of all trials included in our analysis.
By current methods standards, trial quality was suboptimal. In addition, many trials were not reported according to the CONSORT (Consolidated Standards of Reporting Trials) statement (Figure 1) (38, 39) . None of the 27 trials reported the details of allocation concealment (the method by which the person responsible for treatment allocation is made unaware of a participant's treatment assignment). Twelve of 16 trials published before 2004 did not conduct analysis by the intention-to-treat principle, whereas all but 1 of 11 trials from 2004 onward analyzed data according to randomized treatment allocation. Study attrition was higher in studies before 1998 (median, 15%; IQR, 2 to 32%) than in studies from 1998 onward (median, 2%; IQR, 0 to 9%). Larger trials that explored major patientlevel outcomes (all-cause mortality or major adverse cardiovascular events) were generally of better methodological quality.
Meta-analysis
Risks for fatal and nonfatal stroke, vascular access thrombosis, and worsening hypertension were increased with a higher hemoglobin target than with a lower hemoglobin target (Figure 2) . Important heterogeneity among trials for hypertension findings was explored through metaregression. Patients randomly assigned to a higher hemo- We assessed study risk for bias according to recommendations from the Cochrane Collaboration (20) . * Whether the study reported methods to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been predicted in advance of patient enrollment. † Methods by which patients, investigators, or outcomes assessors are protected from being aware of the treatment allocations after patients are included in the study. ‡ Whether the study conducted the major analyses according to the patients' treatment assignment at the time of randomization. § Whether the study described the completeness of outcome data for the primary outcomes. (7, 13, 22, 24, 31, 33) . Heterogeneity in the analysis for iron treatment (heterogeneity chi-square ϭ 21.38; P Ͻ 0.001) was possibly due to more frequent use of iron supplementation in older, placebo-controlled trials. We found no statistically significant difference in the risk for all-cause mortality, serious cardiovascular events, or fatal and nonfatal myocardial infarction between a higher hemoglobin target and a lower target (Figure 2) . In the 10 studies conducted in people with CKD who were not dialysis-dependent, the risk for endstage kidney disease requiring renal replacement therapy did not statistically significantly differ when hemoglobin target groups were compared (Figure 2) . We also found no statistically significant differences between treatment groups in left ventricular mass at the end of treatment (4 trials; 1544 patients; mean difference, 0.14 g/m 2 [CI, Ϫ4.60 to 4.88 g/m 2 ]) (24, 34 -36) . We rated the evidence for treatment effects on quality of life to be of low quality, with high risks for bias due to selective reporting of outcomes. Appendix Table 4 (available at www.annals.org) summarizes the quality-of-life data reported in 15 trials. The Short Form-36 Health Survey (SF-36) was the most commonly used tool for assessment of quality of life, reported in 9 trials (18, 22-24, 29, 30, 35-37) . The SF-36 assesses 8 domains: limitation of physical activity, social function, physical role, bodily pain, mental health, emotional role, vitality, and general health perception. Of importance, only 2 trials reported treatment effects on quality of life for all 8 of the SF-36 outcome domains (23, 37) and only 1 trial (7) reported treatment effects on utility. The most recent, large, and well-designed trial reported no differences in mean change in scores between groups for energy or physical function quality-of-life domains.
Cumulative Meta-analysis
We performed a cumulative meta-analysis to identify when evidence for the benefits and harms of ESA therapy first became evident. Collectively, small placebo-controlled trials conducted before 1998 showed effect estimates favoring a higher hemoglobin target for all-cause mortality, serious cardiovascular events, and nonfatal and fatal stroke (Figure 3) , whereas larger, active comparator trials with higher hemoglobin targets conducted from 1998 onward favored a lower hemoglobin target and showed risk for harm when targeting higher values. Specifically, when the first trial to include more than 1000 patients was completed in 1998 (22) , cumulative evidence for a probable increased risk for death with a higher hemoglobin target became apparent. Across the following decade, the accrual of 12 further trials with 8233 additional patients and 1063 events did not materially influence the point estimates or confidence intervals for excess mortality that were first identified in 1998.
A probable increased risk for serious cardiovascular events with a higher hemoglobin target was evident in 2006 after trials had randomly assigned 2670 patients (433 events), and this risk remained consistent across subsequent trials that enrolled 4210 patients with 1245 additional events. A probable increase in the risk for stroke with ESA treatment to a higher hemoglobin target was first indicated in 1998 and was confirmed by the placebocontrolled trial by Pfeffer and colleagues (18) . Evidence for increased risks for worsening hypertension and vascular access thrombosis with a higher hemoglobin target was evident from trials conducted in 1990, with point estimates unchanged and increased precision for treatment effects available for these outcomes over time.
Investigation for Sources of Heterogeneity
We conducted subgroup analyses and univariate metaregression to explore trial-level factors (patients, intervention, and design) that may affect the risks for all-cause mortality, worsening hypertension, and stroke (fatal and nonfatal) (Appendix Table 5 , available at www.annals .org). When the 2 primary trial designs were compared (placebo-controlled vs. active ESA comparator), the treatment comparison did not influence the risk for all-cause mortality or stroke. The stage of kidney disease (dialysis vs. predialysis) was not an effect modifier for any of the examined outcomes, suggesting that the findings of this metaanalysis may be generalized to any stage of CKD. When we explored the reasons for heterogeneity in the risk for worsening hypertension, we found a lower risk with a higher hemoglobin target in longer trials, trials with more participants, and trials where adjudication of outcomes was not blinded. As the prescribed ESA dose and the hemoglobin level achieved were inconsistently reported across trials (as seen in Appendix Table 2 , available at www.annals.org), we could not further explore the possible role of these factors on the risk for any outcome.
DISCUSSION
We found that treatment with either erythropoietin or darbepoetin to higher target hemoglobin levels in patients with CKD (any stage) increased the risk for stroke, worsening hypertension, and vascular access thrombosis, compared with treatment to a lower hemoglobin target. We found no statistically significant differences between higher and lower hemoglobin targets for the risk for all-cause mortality, serious cardiovascular events, or end-stage kidney disease, but point estimates for all outcomes favored a lower hemoglobin target and effectively excluded the likelihood of any clinically relevant benefit for a higher hemoglobin target. Targeting a higher hemoglobin level was linked to a reduction in need for red blood cell transfusions but greater prescription of intravenous iron therapy. We Cumulative meta-analysis demonstrated that evidence for harm associated with ESA therapy to achieve higher hemoglobin targets has remained stable since it became apparent in 1998. Before 1998, small placebo-controlled trials with relatively lower hemoglobin targets suggested that adverse clinical outcomes in CKD might be prevented with partial anemia correction compared with no treatment. In these earliest studies, ESA therapy alleviated the need for red blood cell transfusions, and therefore the need to test erythropoietin against placebo in a large trial was not advocated until more recently. A switch to larger trials in 1998 targeting higher hemoglobin values unexpectedly demonstrated that these higher hemoglobin targets were harmful. Addition of 12 further trials after 1998 did not alter the probable increased risks for mortality that was first identified by Besarab and colleagues (22) , although the trials supporting this conclusion all compared 2 different doses of ESA therapy. A placebo-controlled trial of ESA therapy was conducted (TREAT [18] ). Now completed, this large trial tested whether treatment with darbepoetin to achieve a hemoglobin target of about 130 g/L would "beat" placebo (rescue ESA therapy at a hemoglobin level Ͻ90 g/L) (40) . It confirmed that, apart from preventing red blood cell transfusions, treating anemia with ESA therapy is not efficacious and is in fact harmful.
Consistent with these data, increased mortality associated with higher hemoglobin targets using ESA treatment has also been demonstrated in patients with anemia and cancer. A meta-analysis of individual-patient data of erythropoietin or darbepoetin versus placebo (53 trials; 13 933 patients) found that treatment with an ESA was associated with significantly worse overall survival than was no treatment (hazard ratio, 1.06 [CI, 1.00 to 1.12]) (41, 42) . Although a much smaller meta-analysis of placebo-controlled trials of ESA versus placebo (7 trials; 650 patients) in patients with anemia and heart failure did not find a relationship between ESA treatment and mortality (43), a large, event-driven study of darbepoetin versus placebo is currently under way in patients with New York Heart Association class II to IV heart failure and anemia (hemoglobin target, 90 to 120 g/L) (RED-HF [Reduction of Events with Darbepoetin alfa in Heart Failure] trial) (44) . The consistency of our findings compared with those identified in other populations suggests that the design of any ongoing trial in this setting must be carefully assessed. Our findings are also consistent with those of a previous metaanalysis of 8 trials evaluating target hemoglobin levels in CKD that showed an increase in the risk for all-cause mortality with higher hemoglobin levels (RR for all-cause mortality, 1.17 [CI, 1.01 to 1.35]) (17) . We provide a more precise estimate (that is, a narrower confidence interval) of mortality risk (18 trials) (RR, 1.09 [CI, 0.99 to 1.20]) with higher hemoglobin targets than that previously reported by including more trials and patients. Of note, the lack of statistical significance found in the present meta-analysis for mortality is probably due to the smaller point estimate that we found (9% vs. 17%), which is, however, consistent with that reported in the larger meta-analysis of trials in patients with cancer (42) .
In the absence of a survival advantage for ESA therapy, improving quality of life has become the key rationale for treating anemia in CKD. We found that evidence for quality of life was suboptimal because of selective reporting, suggesting potential overestimation of the benefits of anemia correction. Data from large and well-conducted trials did not support clinical efficacy for ESA therapy on quality of life (18) . We found that ESA therapy was associated with a reduction in the need for blood transfusions, although the clinical relevance of this observation needs to be considered in light of the harms demonstrated in randomized trials of ESA to date, increased rates of intravenous iron therapy associated with higher hemoglobin targets, expense of ESA administration, and relatively low risks for transfusion-associated infection in the modern era.
Targeting higher hemoglobin levels with ESA therapy worsens hypertension. Although greater risks for hypertension were evident in smaller studies of lower quality and with shorter follow-up, larger trials with lower risks for bias also demonstrated increased risks for worsening hypertension with a higher hemoglobin target. The hypertensive effects of ESA therapy in the higher hemoglobin target group of all trials to date suggest that ESA therapy might mediate excess vascular events through nonhematopoietic erythropoietin receptor activation in vascular tissues (45) , although this hypothesis remains speculative.
Using subgroup and meta-regression analysis, we identified consistent treatment-related risks for death and stroke associated with higher hemoglobin levels across all trials. Risks were similar across all stages of CKD and were not dependent on trial method quality or intervention. We could not specifically address the important question of whether the increased risk for adverse outcomes with higher hemoglobin levels was due to the ESA dose required in the individual patient to achieve the targeted hemoglobin level rather than the hemoglobin target (46 -48) . Understanding the independent effect of ESA dose on outcomes in CKD now demands that treatment dose (and not hemoglobin target) is the randomized intervention in adequately powered trials and that dose and other data from existing trials should be made available for more refined analyses. Our findings indicate that, on the basis of the available trial evidence, the rationale for the recommended hemoglobin target of 110 to 120 g/L in the National Kidney Foundation clinical practice guideline on recommendations for anemia in CKD is unclear (49, 50). We found no evidence that higher hemoglobin targets in CKD are associated with benefit and conclude that anemia treatment using ESA is associated with possible or absolute harm across all major clinical outcomes.
Our review has limitations. First, the evidence for ESA therapy to improve quality of life is based largely on selective reporting of outcomes and is generally of low quality. Second, the available trial data do not identify the mechanisms by which ESA therapy may be harmful. Third, trials reported insufficient information to allow analysis of the independent effects of ESA dose on outcomes. A metaanalysis of individual-patient data might allow preliminary exploration of the specific patient and intervention characteristics that predict harm with ESA therapy.
In conclusion, ESA therapy targeting higher hemoglobin levels leads to increased risks for vascular and fatal events compared with therapy targeting lower levels. Evidence for harm when targeting higher hemoglobin values in CKD has now been available for more than 20 years, and this evidence should be incorporated in guidelines and adopted in clinical practice. The case is strong for making the best use of the considerable amount of information on hemoglobin targets available in existing trials by conducting meta-analysis of individual-patient data. The nephrology community should focus strongly on exploring these existing data and designing, conducting, and achieving funding for fixed-dose ESA trials. and congestive heart failure, ischemic heart disease, or both
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